Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma- Initiating Cells
- Characterizing EVA1 membrane protein as an unexplored target to eliminate Glioblastoma-Initiating Cells (GICs)
- Generating high affinity anti-EVA1 antibodies to assess antibody dependent cytotoxicity and complement dependent cytotoxicity
- Exploring non-clinical performance of B2E5-ADC in EVA1 expressing cell lines and GICs in culture